The Latest Breaking News from IDEXX

IDEXX Laboratories is set to announce its third-quarter results next month, with analysts forecasting robust double-digit growth in earnings.

IDEXX Laboratories' stock has significantly outperformed the broader market over the past year, but analysts are cautiously bullish about its growth potential.

Despite IDEXX Laboratories’ underperformance relative to the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

IDEXX Laboratories has significantly outperformed the broader market in 2025 and analysts remain bullish on the stock’s prospects.

IDEXX Laboratories has continued to underperform the S&P 500 over the past year, yet analysts remain moderately bullish on the stock’s prospects.

5 analysts have shared their evaluations of IDEXX Laboratories (NASDAQ:IDXX) during the recent three months, expressing a mix of bullish and bearish perspectives.

IDEXX Laboratories underperformed the broader healthcare sector, but Wall Street analysts remain moderately optimistic about the stock’s prospects.

Smith's popular fund has again underperformed the benchmark, prompting him to defend his Nvidia stance once more.

With an aging population worldwide, the rising prevalence of chronic diseases, and numerous technological advancements, the medical device sector stands primed for considerable growth and expansion. The industry tailwinds should benefit medical device stocks T2 Biosystems (TTOO) and IDEXX Laboratories (IDXX). However, which stock is poised for better gains this…